AnaptysBio (NASDAQ:ANAB) Stock Price Down 3.3%

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price fell 3.3% during trading on Monday . The stock traded as low as $25.45 and last traded at $25.69. 72,883 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 334,471 shares. The stock had previously closed at $26.58.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ANAB. Piper Sandler began coverage on shares of AnaptysBio in a research report on Friday, February 16th. They issued an “overweight” rating and a $80.00 price target for the company. Wells Fargo & Company began coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target for the company. JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, April 1st. Stifel Nicolaus began coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They issued a “buy” rating and a $50.00 target price for the company. Finally, Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $46.22.

AnaptysBio Trading Down 3.0 %

The firm has a market cap of $704.04 million, a P/E ratio of -4.24 and a beta of -0.32. The business’s fifty day moving average price is $22.91 and its two-hundred day moving average price is $20.86.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The business had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. Research analysts predict that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Activity

In other news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the transaction, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the transaction, the chief executive officer now owns 749,087 shares in the company, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider now owns 3,240 shares in the company, valued at approximately $81,000. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 153,940 shares of company stock worth $3,513,773. 33.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio in the 1st quarter valued at $38,000. China Universal Asset Management Co. Ltd. grew its stake in AnaptysBio by 350.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 2,390 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in AnaptysBio by 134.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 3,381 shares during the last quarter. Quest Partners LLC acquired a new position in AnaptysBio in the 4th quarter valued at $119,000. Finally, SG Americas Securities LLC acquired a new position in AnaptysBio in the 4th quarter valued at $126,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.